トカイニド

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P330：口をすすぐこと。

  P501：内容物/容器を．．．に廃棄すること。

トカイニド 価格

トカイニド 化学特性,用途語,生産方法

• 効能

  抗不整脈薬, ナトリウムチャネル遮断薬

• 使用

  Tocainide is used for suppressing symptoms of ventricular arrhythmia and tachycardia, and for premature cardiac contractions.

• 定義

  ChEBI: A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.

• 世界保健機関（WHO）

  Tocainide, an antidysrhythmic agent, was introduced in 1981 for the treatment of ventricular dysrhythmias. By 1984 its use was associated with cases of agranulocytosis, aplastic anaemia and thrombocytopenia, some of which were fatal. This led some regulatory authorities to restrict the indications for its use. The major manufacturer has subsequently restricted its use on a worldwide basis to the treatment of symptomatic ventricular dysrhythmias not responding to other therapy, or when other therapy is contraindicated.

• 薬物動態学

  The α-methyl group is believed to slow the rate of metabolism and, thereby, to contribute to oral activity. The plasma half-life of tocainide is approximately 12 hours, and nearly 50% of the drug may be excreted unchanged in the urine. Adverse effects associated with tocainide are like those observed with lidocaine—specifically, gastrointestinal disturbances and central nervous system effects.

• 臨床応用

  Tocainide (Tonocard) is an orally effective antiarrhythmic agent with close structural similarities to lidocaine. Tocainide is indicated for the treatment of symptomatic ventricular arrhythmias refractory to more conventional therapy. Serious noncardiac adverse effects limit its use to patients with life-threatening arrhythmias.

• 副作用

  Light-headedness, dizziness, or nausea occurs in approximately 15% of patients, paresthesias and numbness in 9%, and tremor in 8%.These adverse effects are generally mild in intensity, transient, and dose related. Overall, however, approximately 20% of patients prescribed tocainide discontinue therapy because of such effects. Serious immune-based side effects, such as pulmonary fibrosis, have been reported, and blood dyscrasias, such as agranulocytosis and thrombocytopenia, may occur in up to 0.2% of patients.

• 薬物相互作用

  When used with other class IB antiarrhythmic drugs, tocainide toxicity may be increased without significant gain in antiarrhythmic efficacy.

• 予防処置

  Patients who are hypersensitive to tocainide or to local anesthetics of the amide type should not be exposed to tocainide.The presence of second- or third-degree heart block in the absence of an artificial pacemaker also contraindicates the use of tocainide.

トカイニド 上流と下流の製品情報

トカイニド 生産企業

Global(60)Suppliers

トカイニド スペクトルデータ(¹HNMR)

41708-72-9, トカイニド キーワード